<DOC>
	<DOC>NCT00542295</DOC>
	<brief_summary>To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design</brief_summary>
	<brief_title>Efficacy and Safety of MeteospasmylÂ® in Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<criteria>male or female ambulatory patients, aged 1875 years with IBS as defined by Rome III criteria Functional bowel disorder other than IBS, Underlying cause for symptomatology, which excludes IBS diagnosis, Gastrointestinal cancer or significant gastrointestinal surgical background, Any acute/uncontrolled systemic pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>